报告题目：Pharmacological Modulation of multiple CRISPR systems and the Hedgehog Pathway
报 告 人：王宇 博士（中科院动物所）
Yu Wang, Ph.D., is currently a professor at the Institute of Zoology, Chinese Academy of Sciences. He received his bachelor degree from University of Science and Technology of China in 2004 and his Ph.D. from Harvard University in Department of Chemistry and Chemical Biology in 2010, under the supervision of Dr. Andrew P. McMahon. He subsequently worked as a postdoctoral fellow with Dr. Andrew P. McMahon and Dr. Lee L. Rubin at Harvard and later as a research associate with Dr. James A. Thomson at Morgridge Institute for Research. His work has been published in high profile journals including PNAS, JACS, Nucleic Acids Research, Cell Chemical Biology, Molecular Therapy-Mucleic Acids, ACS Chemical Biology, and Current Opinion in Cell Biology. He is also an inventor for 2 patents on screening technologies and small molecule drug leads, and 4 patents covering multiple drug inducible devices for genome editing and transcriptional activation.
We have developed a series of novel chemical biology tools, namely HIT systems, by pharmacological modulation of nuclear translocation of Cas protein in the CRISPR systems. These systems delivered advantageous performances over existing ones and are finding broad utilities in many directions. They allow us to conduct genome editing, transcriptional activation, protein labeling in greater precision and flexibility. And we have identified new compounds and mechanisms that modulate defined pathways and mechanisms commonly involved in cancer and regeneration, namely, Hedgehog (Hh) signaling pathway, a central player in tumorigenesis and regeneration in multiple organs.